BISSANTZ CATERINA,JABLONSKI PHILIPPE,KNUST HENNER,NETTEKOVEN MATTHIAS,PATINY ADAM ANGELIQUE,RATNI HASANE,RIEMER CLAUS
申请号：
IN2372/CHENP/2011
公开号：
IN2011CN02372A
申请日:
2011.04.07
申请国别(地区):
IN
年份:
2015
代理人:
摘要：
The present invention relates to a compound of formula I N -Ar ° , wherein Ar1 is aryl or heteroaryl Ar2 is aryl or heteroaryl R1 is hydrogen, halogen, hydroxy, lower alkyl, lower alkoxy, lower alkyl substituted by halogen, lower alkoxy substituted by halogen, S-lower alkyl, -S(0)2-lower alkyl, -S(0)2-di-lower alkyl amino, cyano, amino, mono or di-lower alkyl amino, C(0)-lower alkyl, NHC(0)-lower alkyl, cycloalkyl, heterocyclyl, or is heteroaryl, optionally substituted by lower alkyl R2 is hydrogen, halogen, lower alkyl, lower alkoxy, lower alkyl substituted by halogen or cyano R3. is hydrogen, halogen, lower alkyl or lower alkyl substituted by halogen n is 1, 2 or 3 in case n is 2 or 3, R1 may be the same or different o is 1, 2 or 3 in case o is 2 or 3, R2 may be the same or different p is 1, 2 or 3 in case p is 2 or 3, R4 may be the same or different or to a pharmaceutically active salt, to all stereoisomeric forms, including individual diastereoisomers and enantiomers as well as to racemic and non-racemic mixtures thereof. It has been found that the present compounds are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinsons disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).
